Market Cap | 866.43M | P/E | - | EPS this Y | 13.30% | Ern Qtrly Grth | - |
Income | -65.14M | Forward P/E | -36.73 | EPS next Y | 73.10% | 50D Avg Chg | 13.00% |
Sales | 210M | PEG | -0.88 | EPS past 5Y | - | 200D Avg Chg | 27.00% |
Dividend | N/A | Price/Book | 7.15 | EPS next 5Y | 30.00% | 52W High Chg | -21.00% |
Recommedations | 1.50 | Quick Ratio | 3.58 | Shares Outstanding | 235.43M | 52W Low Chg | 453.00% |
Insider Own | 1.62% | ROA | -13.27% | Shares Float | 229.90M | Beta | 0.89 |
Inst Own | 61.83% | ROE | -48.23% | Shares Shorted/Prior | 25.93M/25.98M | Price | 4.04 |
Gross Margin | 66.27% | Profit Margin | -31.02% | Avg. Volume | 5,148,887 | Target Price | 11.65 |
Oper. Margin | -18.62% | Earnings Date | Oct 29 | Volume | 10,175,200 | Change | 5.21% |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Jan 08 | Sell | 6.64 | 30,000 | 199,200 | 286,596 | 01/10/24 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Dec 26 | Sell | 6.36 | 225,000 | 1,431,000 | 182,426 | 12/28/23 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Dec 26 | Option | 0.99 | 75,000 | 74,250 | 407,426 | 12/28/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Dec 18 | Sell | 6.07 | 5,675 | 34,447 | 316,596 | 12/20/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Dec 14 | Sell | 5.55 | 7,000 | 38,850 | 322,271 | 12/15/23 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Dec 11 | Sell | 5.0785 | 50,000 | 253,925 | 275,675 | 12/13/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Dec 08 | Sell | 5.2738 | 20,000 | 105,476 | 329,271 | 12/08/23 |
Williams Laura A | Chief Medical Office.. Chief Medical Officer | Nov 20 | Sell | 4.3622 | 2,581 | 11,259 | 266,191 | 11/22/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Nov 20 | Sell | 4.36 | 3,767 | 16,424 | 113,293 | 11/22/23 |
Rodriguez Susan | Chief Commercial Off.. Chief Commercial Officer | Nov 20 | Sell | 4.3622 | 4,714 | 20,563 | 346,973 | 11/22/23 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Nov 20 | Sell | 4.3622 | 2,873 | 12,533 | 332,426 | 11/22/23 |
RAAB MICHAEL | President & CEO President & CEO | Nov 20 | Sell | 4.3622 | 11,368 | 49,589 | 867,868 | 11/22/23 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Nov 20 | Sell | 4.3622 | 2,384 | 10,399 | 325,675 | 11/22/23 |
Felsch Robert Ora | See Remarks See Remarks | Nov 20 | Sell | 4.3622 | 1,044 | 4,554 | 117,066 | 11/22/23 |
Blanks Robert | See Remarks See Remarks | Nov 20 | Sell | 4.3622 | 2,835 | 12,367 | 260,453 | 11/22/23 |
Williams Laura A | Chief Medical Office.. Chief Medical Officer | Nov 15 | Sell | 3.9999 | 25,000 | 99,998 | 266,839 | 11/17/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Oct 10 | Sell | 4 | 1,644 | 6,576 | 365,378 | 10/12/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Sep 08 | Sell | 4.55 | 2,897 | 13,181 | 367,022 | 09/12/23 |
Williams Laura A | Chief Medical Office.. Chief Medical Officer | Jun 27 | Sell | 3.3453 | 25,000 | 83,632 | 294,430 | 06/29/23 |
Blanks Robert | See Remarks See Remarks | Jun 23 | Sell | 3.63 | 33,333 | 120,999 | 266,134 | 06/27/23 |
Blanks Robert | See Remarks See Remarks | Jun 23 | Option | 3.42 | 33,333 | 113,999 | 299,467 | 06/27/23 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Mar 29 | Sell | 4.6293 | 3,000 | 13,888 | 113,096 | 03/31/23 |
Felsch Robert Ora | See Remarks See Remarks | Aug 31 | Buy | .6188 | 3,000 | 1,856 | 91,418 | 09/01/22 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Aug 31 | Buy | 0.62 | 3,000 | 1,860 | 92,369 | 09/01/22 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Aug 31 | Sell | 0.92 | 3,000 | 2,760 | 89,369 | 09/01/22 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Aug 31 | Buy | 0.6188 | 3,000 | 1,856 | 263,549 | 09/01/22 |
Williams Laura A | Chief Medical Office.. Chief Medical Officer | Aug 31 | Buy | 0.6188 | 3,000 | 1,856 | 245,441 | 09/01/22 |
RAAB MICHAEL | President & CEO President & CEO | Aug 31 | Buy | 0.6188 | 3,000 | 1,856 | 665,680 | 09/01/22 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Aug 31 | Buy | 0.6188 | 3,000 | 1,856 | 256,110 | 09/01/22 |
Rodriguez Susan | Chief Commercial Off.. Chief Commercial Officer | Aug 22 | Sell | 0.98 | 3,420 | 3,352 | 286,173 | 08/24/22 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Aug 22 | Sell | 0.98 | 1,955 | 1,916 | 89,369 | 08/24/22 |
Blanks Robert | See Remarks See Remarks | Aug 22 | Sell | 0.98 | 1,458 | 1,429 | 317,669 | 08/24/22 |
RAAB MICHAEL | President & CEO President & CEO | Aug 22 | Sell | 0.98 | 6,146 | 6,023 | 662,680 | 08/24/22 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Aug 22 | Sell | 0.98 | 1,236 | 1,211 | 253,110 | 08/24/22 |
Williams Laura A | Chief Medical Office.. Chief Medical Officer | Aug 22 | Sell | 0.98 | 1,276 | 1,250 | 242,441 | 08/24/22 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Aug 22 | Sell | 0.98 | 1,498 | 1,468 | 260,549 | 08/24/22 |
Renz Justin A | Chief Financial Offi.. Chief Financial Officer | Jun 06 | Sell | 0.64 | 73,312 | 46,920 | 262,047 | 06/08/22 |
Rodriguez Susan | Chief Commercial Off.. Chief Commercial Officer | Jun 06 | Sell | 0.64 | 43,920 | 28,109 | 289,593 | 06/08/22 |
Blanks Robert | See Remarks See Remarks | Jun 06 | Sell | 0.64 | 73,312 | 46,920 | 324,315 | 06/08/22 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Jun 06 | Sell | 0.64 | 60,821 | 38,925 | 254,346 | 06/08/22 |
Rosenbaum David P. | Chief Development Of.. Chief Development Officer | Jun 06 | Sell | 0.64 | 61,640 | 39,450 | 89,866 | 06/08/22 |
RAAB MICHAEL | President & CEO President & CEO | Jun 06 | Sell | 0.64 | 103,624 | 66,319 | 668,826 | 06/08/22 |
Blanks Robert | See Remarks See Remarks | Feb 22 | Sell | 0.67 | 1,752 | 1,174 | 399,116 | 02/25/22 |
SANDELL SCOTT D | 10% Owner 10% Owner | Dec 09 | Sell | 1.32 | 2,881,570 | 3,803,672 | 2,258,850 | 12/27/21 |
BASKETT FOREST | 10% Owner 10% Owner | Dec 09 | Sell | 1.32 | 2,881,570 | 3,803,672 | 2,258,850 | 12/27/21 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Dec 15 | Option | 2.32 | 42,000 | 97,440 | 113,527 | 12/15/20 |
GRAMMER ELIZABETH A | See Remarks See Remarks | Dec 15 | Sell | 7.3 | 42,000 | 306,600 | 72,527 | 12/15/20 |